MedTrace Logo

Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC

NCT07743632 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-08-04

No results posted yet for this study

Summary

This study will test the effectiveness of two standard neoadjuvant chemotherapy regimens plus an investigational drug (ivonescimab) that has dual action as both immunotherapy and therapy targeting the tumor's blood supply. This investigational drug is called ivonescimab.

Conditions

Interventions

DRUG

Carboplatin

Commercially available

DRUG

Docetaxel

Commercially available

DRUG

Doxorubicin

Commercially available.

DRUG

Cyclophosphamide

Commercially available.

DRUG

Ivonescimab

Ivonescimab is a bispecific antibody targeting PD-1 and VEGF. Ivonescimab will be supplied for participants by Summit Therapeutics.

Sponsors & Collaborators

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Priyanka Sharma, MD · The University of Kansas Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2032-12-31
Completion
2033-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07743632 on ClinicalTrials.gov